Publicación de Buenavista Equity Partners (formerly GED Capital)

🔊 Canaan Partners, a venture capital firm, recently secured over $100 million, adding to the $850 million fund announced last year. 🔊 This boost in capital, according to General Partner Julie Grant, is earmarked for biotech investments, supplementing the firm's existing strategy of investing in early-stage companies in the biopharma sector. With this injection, Canaan's total raised funds since early 2023 now exceed $1 billion, with a significant portion allocated to healthcare ventures. In addition to financial growth, Canaan has expanded its team with the addition of Uwe Schoenbeck, Ph.D., a former senior executive at Pfizer. Schoenbeck's expertise in bridging early science and biotech startups aligns well with Canaan's investment focus. While Canaan has yet to explore the metabolic disease arena, Schoenbeck anticipates targeted investments in the broader cardiometabolic space in the future. Canaan's recent investments include contributions to biotech raises for Nocion Therapeutics, Inc. and Alterome Therapeutics, Inc, showcasing its commitment to advancing innovative healthcare solutions. Full article: https://lnkd.in/ecpRi8fy

#Terumo anunció hoy que ha establecido “Terumo Ventures”, una organización de Capital de Riesgo Corporativo responsable de liderar la inversión de riesgo del grupo, como un departamento dentro de Terumo Americas Holding, Inc.   Terumo Ventures opera en centros de innovación globales en todo el mundo, como Massachusetts y California en los EE. UU., e invertirá US$75 millones durante los próximos cinco años en empresas en etapa inicial, principalmente en el campo del tratamiento de enfermedades cardiovasculares, tratamiento de enfermedades crónicas, tecnologías de sangre y células, y tecnologías digitales. Esto permitirá a Terumo mejorar su acceso a tecnologías innovadoras e ideas comerciales de empresas emergentes, así como promover la innovación abierta. ✅Comunicado de prensa: https://lnkd.in/eYHHa2wb ✅Formulario de solicitud: https://lnkd.in/eHS4TfVp  #TerumoVentures #innovación #Medtech #CVC #capitalderiesgo #startups #tecnología

2023 closing of Equity Value and Venture Capital operations. #sarahschwartzabogadaamericanaenmadrid #venturecapital #privateequity #scaleups #startups #abogadostartups #travel #viajes #mobility #smartcities #inversionstartups #startupsespañolas #inversión #scalesupspain #startupspain

Milan, Italy based XGEN Venture recently launched its first life science fund 💸 €160 million backed by European Investment Fund (EIF), CDP Venture Capital SGR, Micheli Associati, UniCredit, Quaestio Capital SGR S.p.A., BancoBPM, Inarcassa, ENPAM, Fondazione di Sardegna and Banca Sella Holding. The firm is targeting a final close of €200 million. 💡 Investing in 15 #lifescience focused early-stage breakthrough opportunities that are delivering impact to patients through new #therapeutics, #medicaldevices, #diagnostics and #digitalhealth solutions. 🌍 #Europe 📈 So far they have invested in five companies including PAGE Therapeutics AG, Protembis GmbH, Tes Pharma S.r.l., Genespire and Nouscom 💭 “This new fund will allow us to continue our established strategy of building and growing companies that conduct complex clinical programs for serious health conditions.” - XGEN Venture 🗞️Business Wire https://lnkd.in/damY5t48 👏 For the #AudaciousInvestors unleashing innovation and empowering tomorrow🚀 Federica I Paolo I Daniele I Mariagiulia I Roberto I Simona I Team XGEN Venture … #venturecapital #vc #funds #startups #entrepreneurs #funding #tech #entrepreneurship #technology #innovation #Milan #Italy #venture #fund

Clave Capital, entre algunas de las empresas inversoras más activas de 2023. Según un estudio reciente de Biocat, BioRegion of Catalonia, el año pasado, y en contraste con la tendencia de los últimos cuatro años, las empresas de inversión nacionales experimentaron un crecimiento por encima de la media, alcanzando un total de 36, lo que supone el doble de inversores en comparación con 2019. 📃 El informe, que también menciona a compañías de la talla de CaixaBank o Ship2B Ventures, posiciona así a nuestra gestora entre las más activas del año pasado. 𝗠𝗮́𝘀 𝗶𝗻𝗳𝗼𝗿𝗺𝗮𝗰𝗶𝗼́𝗻: https://report.biocat.cat/ #ClaveCapital #CapitalRiesgo #EmpresaClave #inversión #innovación #informe

Delft-based Oasys NOW wins Slush 100 competition; wins €1M equity investment: Delft-based OASYS NOW, the EU’s first AI-powered patient recruitment platform, has been announced as the winner of Slush 100 after pitching live on the international summit’s Startup Stage. The Dutch company wins €1M equity investment from two of Europe’s most prominent early-stage venture funds: General Catalyst and Cherry Ventures.  Additionally, the company will also get ... #OASYSNOW #Slush100

Fund-Raised Global Digital Therapeutics (DTx) Startups - Investors Mapping Through an extensive search and review of publicly available information, 172 startups were selected for detailed analysis regarding their fundraising status. Among these, 94 Digital Therapeutics (DTx) startups have collectively raised $6.859 billion from global investors. These startups include Raft Digital Therapeutics, Mindable Health GmbH, MicroHealth, Vigo Health, SleepUp, Vitadio s.r.o., Neurolief, OPTT Health, Vivira Health, XR Therapeutics, and many others. They are supported by a diverse range of investors, such as aMoon Fund, Expansion Capital, UV-Cap, 7wireVentures, Accelmed Partners, Adage Capital Management, and BCG Digital Ventures, among others. This substantial funding highlights the growing investor confidence and interest in DTx innovations. #dtx #digitaltherapeutics #startup #vc #funding #fundraising #investment

El valenciano Damia Tormo cierra su cuarto fondo de 150 millones para invertir en 'biotech' COLUMBUS VENTURE PARTNERS,S.G.E.I.C., S.A.U. , gestora de capital riesgo española enfocada en inversiones en el sector biotecnológico y cofundada por el valenciano Damià Tormo junto a Javier García, ha cerrado su curto fondo de inversión, de 150 millones de euros. Éste fue aprobado por la CNMV (Comisión Nacional del Mercado de Valores)) en marzo de 2023, con el propósito de invertir en el sector biotech y farmacéutico. Denominado Columbus Life Sciences Fund IV, como en los tres anteriores, seguirá la estrategia de invertir tanto en investigación y desarrollo de terapias como en la producción industrial de tratamientos innovadores. Lo hará tanto en España como en empresas internacionales con una docena de inversiones que rondarán los 10 millones de euros. Columbus seguirá creando empresas desde su inicio, construyendo los negocios alrededor de equipos de gestión probados o de activos provenientes de la academia o de la industria farmacéutica. #Farmacéutica #Biotech #Biotecnología #Inversión

En este #LociTraining vas a aprender todo lo que tenes que saber sobre #GMP y #GLP, Cuando empezar? Cómo incorporarlo?, que significa “GMP Compliance (cGMP)”? Veni a subir el nivel a Loci Labs !

New Foresite Capital Fund VI at $900M🌟 Foresite Capital has successfully raised $900M for its sixth fund, aimed at investing in life sciences companies. Despite its impressive track record, including 47 IPOs, 28 M&As, and 58 FDA-approved drugs, the San Francisco-based firm faced challenges in its fundraising efforts. The process took two years, reflecting the broader difficulties in venture fundraising in recent years. CEO and founder Jim Tananbaum noted that while almost all of their LPs from Fund V renewed their commitments, they did so with 30% less capital. This created a funding gap that needed to be addressed. To bridge this gap, Foresite hired Hadi Tabbaa, formerly of B Capital and Coatue Management, to lead the firm's investment relations effort and attract new LPs, including family offices from Asia and the Middle East. The firm's Fund V totaled $969M, comprising a $775M core fund and a $194M companion opportunities fund. Foresite was determined to ensure that Fund VI would not be significantly smaller, and their efforts paid off. On Wednesday, the firm announced the closing of its sixth fund at $900M. Foresite began investing from the sixth fund nearly two years ago and has since backed several notable companies. One significant investment was in April, when Foresite Labs, in collaboration with ARCH Venture Partners, invested $1B to incubate Xaira, an AI drug discovery startup. Additionally, the firm participated in the $135M Series A of Latigo Biotherapeutics, Inc., a clinical-stage biotech company developing a non-opioid pain treatment. Last summer, Foresite co-led a $115M Series F round for CG Oncology, a drug discovery company that had a successful IPO in January. The firm plans to back around 20 companies with its Fund VI, writing checks ranging from a few million dollars up to $75M. Foresite Capital's focus remains on the intersection of genomics and artificial intelligence, which Tananbaum believes will revolutionize healthcare by enabling personalized care. "Over a decade ago, we named the firm Foresite because we thought we had an idea of where healthcare was headed," Tananbaum explained. "We felt that it was going to be a combination of genomics and artificial intelligence that would lead to the ability to distribute care individually." These areas continue to be key focal points for the firm as it moves forward. ✅ Looking to raise capital for your #VCfund and increase the international pool of your LPs?   🤝 Need warm #LP introductions?   📝 Selling #secondaries to increase liquidity?   🧐 Looking for co-investments (Series A/Series B)?   ▶ G+QUANT's link for inquiries and fund decks: https://lnkd.in/gjC_EuTE #LifeSciences #VentureCapital #HealthcareInnovation #Genomics #AIinHealthcare 💊💡